B Cell Lymphoma
From the Journals
CK doesn’t seem to affect OS in CLL patients taking idelalisib
Data from two clinical trials of idelalisib showed no significant difference in overall survival between patients with and without complex...
Conference Coverage
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCL
LUGANO, SWITZERLAND – In patients younger than 65 years old, two cycles of ibrutinib and rituximab followed by four cycles of chemotherapy...
News
Calquence earns breakthrough designation for CLL monotherapy
The Bruton tyrosine kinase inhibitor is already approved for the treatment of adults with mantle cell lymphoma who have received at least one...
From the Journals
Obinutuzumab-lenalidomide combo shows promise in relapsed/refractory FL
In the phase 2 GALEN study, induction with obinutuzumab and lenalidomide followed by maintenance therapy with obinutuzumab appears effective for...
From the Journals
Brentuximab vedotin plus nivolumab shows positive outcomes in PMBL
The CheckMate 436 study showed that the combination may be synergistic and is highly active in relapsed/refractory primary mediastinal B-cell...
From the Journals
Zanubrutinib may be poised to challenge ibrutinib for CLL
The phase 1 study had a 96% overall response rate and there were no dose-limiting toxicities.
Conference Coverage
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCL
LUGANO, SWITZERLAND –The chemotherapy-free combination was associated with a high objective response rate in patients with a median age of 71...
From the Journals
Low-dose radiation therapy looks effective in hard-to-treat MCL
The treatment approach can be used safely with concurrent chemotherapy.
From the Journals
ICYMI: Ibrutinib/rituximab combo improves CLL survival
Progression-free and overall survival were superior in patients receiving ibrutinib and rituximab, compared with standard chemotherapy.
From the Journals
BTK mutations linked to CLL progression on ibrutinib
The findings support mutational analysis in CLL patients on ibrutinib, according to researchers.
News
FDA approves rituximab biosimilar for cancer, autoimmune disorders
The biosimilar is approved for certain cancers and autoimmune disorders, although, like its reference drug, it comes with a boxed warning from the...